Literature DB >> 9074400

Helium and oxygen treatment of severe air-diving-induced neurologic decompression sickness.

A Shupak1, Y Melamed, Y Ramon, Y Bentur, A Abramovich, S Kol.   

Abstract

BACKGROUND: The use of helium and oxygen recompression treatment of neurologic decompression sickness (DCS) has several theoretical advantages over the traditionally used air and oxygen recompression tables that have been confirmed by findings from recent animal experiments.
OBJECTIVES: To evaluate the outcome of patients with neurologic DCS who had been treated with a helium-oxygen protocol and to compare it with that of a retrospective control group that was treated with air-oxygen tables.
DESIGN: The study and control groups included 16 and 17 diving casualties, respectively. The severity of neurologic DCS was estimated according to a 9-point scale weighting motor, sensory, and sphincter control functions. The study group was treated with a helium-oxygen decompression protocol, and the control group was treated with the US Navy air-oxygen Table 6 or 6A. Persistent residual dysfunction was treated in both groups with daily hyperbaric oxygen sessions, at 2.5 absolute atmospheres for 90 minutes, until no further clinical improvement was noted.
SETTING: The Israel Naval Medical Institute (Israel's national hyperbaric referral center), Haifa.
RESULTS: Significant clinical score increments were found for both the helium-oxygen- and air-oxygen-treated groups: 2.8 +/- 2.4 (mean +/- SD) and 7.4 +/- 1.1 at presentation vs 7.6 +/- 2.1 and 8.1 +/- 1.5 at discharge, respectively (P < .001 and P = .005, respectively). Although the score at presentation was significantly lower for the helium-oxygen-treated group (P < .001), no difference was found between the groups' average outcome scores. While most of the improvement in the patients in the study group could be attributed to the helium-oxygen treatment and not to the supplemental hyperbaric oxygen, in the control group, no significant difference could be demonstrated between the scores at presentation and at completion of the air-oxygen recompression table. In 5 patients who were treated with the use of the air-oxygen tables, deterioration was observed after recompression. No deterioration or neurologic DCS relapse occurred in the helium-oxygen-treated group.
CONCLUSION: The results suggest an advantage of helium-oxygen recompression therapy over air-oxygen tables in the treatment of neurologic DCS.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9074400     DOI: 10.1001/archneur.1997.00550150061017

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  5 in total

1.  Prognostic factors of spinal cord decompression sickness in recreational diving: retrospective and multicentric analysis of 279 cases.

Authors:  Jean-Eric Blatteau; E Gempp; O Simon; M Coulange; B Delafosse; V Souday; G Cochard; J Arvieux; A Henckes; P Lafere; P Germonpre; J-M Lapoussiere; M Hugon; P Constantin; A Barthelemy
Journal:  Neurocrit Care       Date:  2011-08       Impact factor: 3.210

Review 2.  Recompression and adjunctive therapy for decompression illness.

Authors:  Michael H Bennett; Jan P Lehm; Simon J Mitchell; Jason Wasiak
Journal:  Cochrane Database Syst Rev       Date:  2012-05-16

Review 3.  Evaluation and management of decompression illness--an intensivist's perspective.

Authors:  Kay Tetzlaff; Erik S Shank; Claus M Muth
Journal:  Intensive Care Med       Date:  2003-11-05       Impact factor: 17.440

4.  Effect of isobaric breathing gas shifts from air to heliox mixtures on resolution of air bubbles in lipid and aqueous tissues of recompressed rats.

Authors:  O Hyldegaard; D Kerem; Y Melamed
Journal:  Eur J Appl Physiol       Date:  2011-02-12       Impact factor: 3.078

5.  Comparison of treatment recompression tables for neurologic decompression illness in swine model.

Authors:  W Rainey Johnson; Nicholas G Roney; Hanbing Zhou; Geoffrey E Ciarlone; Brian T Williams; William T Green; Richard T Mahon; Hugh M Dainer; Brett B Hart; Aaron A Hall
Journal:  PLoS One       Date:  2022-10-05       Impact factor: 3.752

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.